Tools
Stock profile

Warby Parker Inc. (WRBY)

WRBY · Latest close $28.22 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$28.22
As of Nov 18, 2026
Tracked funds holding
4 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
0
vs previous quarter

Warby Parker Inc. (WRBY) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $7.9M sold). Latest close $28.22 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 9, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-7.9M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Durable Capital Partners · SRS Investment Management · Gardner Russo & Quinn — 4 tracked funds hold WRBY. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 5 sales ($7.9M). Insider trading

Often held alongside

COMCAST CORP (CMCSA) · ALCON INC (ALC) · COOPER COMPANIES, INC. (COO) · Bausch & Lomb Corp (BLCO) · National Vision Holdings, Inc. (EYE) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Durable Capital Partners1.89%6,396,513HELD Q3 filed Nov 16
SRS Investment Management0.41%1,453,523ADDED (+1.0%) Q3 filed Nov 16
Gardner Russo & Quinn0.03%80,000HELD Q3 filed Nov 12
First Eagle Investment Management0.01%288,000ADDED (+113.2%) Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -11.8% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

30.3413.352024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding304 of 8,857 filers
Long-only filers among them301
Change vs 2026 Q1+9 net · 293 entered · 284 exited
Shares reported, all filers124,794,142
Reported value, all filers$3.8B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryOphthalmic Goods (SIC 3851)
Revenue · FY2025$871.9M
Net income · FY2025$1.6M
Total assets · FY2025$720.9M
Shares outstanding122,670,000
Market cap (at latest close)$3.5B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 202620,504,550
Share of shares outstanding16.72%
Days to cover7.16

Shares short at recent settlements — Jul 31, 2026: 17.3M · Aug 14, 2026: 18.1M · Aug 31, 2026: 16.3M · Sep 15, 2026: 17.6M · Sep 30, 2026: 18.2M · Oct 15, 2026: 20.5M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 5K · Aug 14, 2026: 16K · Aug 31, 2026: 0 · Sep 15, 2026: 11K · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 5 sales by 3 insiders ($7.9M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 9, 2026Raider Jeffrey JacobSell7,500$30.00$225.0KSEC filing
Nov 9, 2026Gilboa David AbrahamCo-Chief Executive OfficerSell75,402$29.82$2.2MSEC filing
Nov 9, 2026Blumenthal Neil HarrisCo-Chief Executive OfficerSell73,133$30.13$2.2MSEC filing
Oct 1, 2026Raider Jeffrey JacobSell15,000$27.70$415.5KSEC filing
Oct 1, 2026Blumenthal Neil HarrisCo-Chief Executive OfficerSell100,000$27.69$2.8MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 1, 2026JEFFREY RAIDERDirector15,000$416.7KOct 1, 2026SEC filing
Oct 1, 2026NEIL BLUMENTHALDirector, Officer100,000$2.8MOct 1, 2026SEC filing
Jul 6, 2026NEIL BLUMENTHALDirector, Officer9,200$269.2KJul 6, 2026SEC filing
Jul 6, 2026DAVID GILBOADirector, Officer54,347$1.6MJul 6, 2026SEC filing
Jul 1, 2026NEIL BLUMENTHALDirector, Officer217,667$6.6MJul 1, 2026SEC filing
Jul 1, 2026DAVID GILBOADirector, Officer242,221$7.3MJul 1, 2026SEC filing
Jul 1, 2026JEFFREY RAIDERDirector22,500$682.6KJul 1, 2026SEC filing
Jun 29, 2026NEIL BLUMENTHALDirector, Officer36,300$1.1MJun 29, 2026SEC filing
Jun 16, 2026TERESA BRIGGSDirector5,000$131.9KJun 16, 2026SEC filing
Jun 12, 2026YOUNGME MOONDirector10,000$265.3KJun 12, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026Blumenthal Neil HarrisSC 13G/A8,245,0507.2%Jun 30, 2026SEC filing
Jul 8, 2026BlackRock, Inc.SC 13G/A15,035,13414.0%Jun 30, 2026SEC filing
Jun 4, 2026JPMORGAN CHASE & COSC 13G/A10,986,12210.2%May 29, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G5,417,9635.1%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026Durable Capital Partners LPSC 13G/A7,310,6056.9%Dec 31, 2025SEC filing
Jan 23, 2026JPMORGAN CHASE & CO.SC 13G/A9,679,3159.1%Dec 31, 2025SEC filing
Dec 5, 2025FMR LLCSC 13G/A15,858,908.9915.0%Nov 28, 2025SEC filing
Nov 14, 2025Durable Capital Partners LPSC 13G/A8,752,6078.3%Sep 30, 2025SEC filing
Nov 5, 2025FMR LLCSC 13G/A9,272,097.138.8%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Ophthalmic Goods (SIC 3851). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 15 Lobbying Disclosure Act filings named this company as client, 2015–2018; most common issues: Consumer Issues/Safety/Products (13), Health Issues (13).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Growth — Latest revenue: $871.9M · 5-yr revenue CAGR: 17.2% · Straight growth years: 6

· Gross Profitability (Novy-Marx) — Gross profit / assets: 65.3% · Gross margin: 54.0%

· Distress Risk (Altman Z″) — Z″-Score: -0.22 · Working capital / assets: 0.28 · Retained earnings / assets: -0.95 · EBIT / assets: -0.01 · Equity / liabilities: 1.04

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2022 Q1, ranked #33 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together20.0%-25.6%+0.9%-26.5%
Share count tripled (3x)10.0%-29.8%-2.5%-27.3%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold WRBY — ranked by lift, the co-holding pattern described in Methodology: COMCAST CORP (CMCSA) · ALCON INC (ALC) · COOPER COMPANIES, INC. (COO) · Bausch & Lomb Corp (BLCO) · National Vision Holdings, Inc. (EYE) · THERMO FISHER SCIENTIFIC INC. (TMO) · INTUITIVE SURGICAL INC (ISRG) · Medtronic plc (MDT).

7 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 6, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jun 12, 20265.07 Submission of Matters to a Vote of Security HoldersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

COMCAST CORP (CMCSA) · Track Record: how the signals scored · Practice timing on WRBY

One email a week: the week’s new filings and research. Subscribe free

← WRB  ·  WSBF →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.